Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Integrity™ iCELLis™

Product Image
Product Description

iCELLis™, the world’s first fully integrated high-cell density bioreactor is designed to simplify your process, by combining the advantages of single-use technologies with the benefits of a fixed-bed system. Thanks to its compact design - for a quick implementation and more ease of use – iCELLis represents the new generation single-use bioreactors.

Central to the iCELLis bioreactor technology is the use of a compact fixed-bed, filled with custom macrocarriers. This matrix is made of medical grade polyester microfibers and provides in only 25L volume, up to 500m² growth area available to the cells. This surface is equivalent to the surface of 3000 Roller Bottles (1700cm² each). iCELLis bioreactors are supplied pre-packed with macrocarriers. Compared to standard stirred tank bioreactor using microcarriers, the iCELLis technology leads to a dramatic simplification of cell culture process. It enables to avoid delicate and time consuming manual operations: sterilization and hydration of microcarriers, and bead-to-bead transfers from preculture to final process.

With the biomass multiplication occurring in the fixed-bed, iCELLis bioreactors can be inoculated at very low density. The number and volume of pre-culture steps are reduced considerably: 20 Roller Bottles (1700 cm²) are can be sufficient to inoculate an iCELLis 500 bioreactor (500 m² of available surface to the cells). As a consequence of this process simplification, manual operations and associated costs are reduced dramatically.

Evenly-distributed media circulation is achieved by a built-in magnetic drive impeller, ensuring low shear stress and high cell viability. The cell culture medium flows through the fixed-bed from the bottom to the top. At the top, the medium falls as a thin film down the outer wall where it takes up O2 to maintain high KL.a. in the bioreactor. This unique waterfall oxygenation, together with a gentle agitation and biomass immobilization, enables compact iCELLis to achieve and maintain high-cell densities, equaling the productivity of much larger stirred tank units.

Process simplification, from vial thawing to final product, is at the heart of the iCELLis platform. As cells are immobilized in the fixed-bed and iCELLis operates in perfusion mode, there is no need for centrifugation to harvest the cells, which simplifies further the downstream process. Last but not least, in order to reduce process development time, the perfusion device is integrated into the iCELLis™ skid.

Product Integrity™ iCELLis™
Company ATMI LifeSciences
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

ATMI LifeSciences
10851 Louisiana Avenue South Bloomington, Minnesota 55438 USA

Tel: +1.952.942.0855
Fax: +1.952.516.5465



Scientific News
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!